Subsequent Survival and Loss of Lifetime for Patients With Progression‐Free 24 Months After Treatment in Nasopharyngeal Carcinoma: A Comprehensive Nationwide Population‐Based Analysis
Currently, there is little evidence supporting the use of early endpoints to assess primary treatment outcomes in nasopharyngeal carcinoma (NPC). We aim to explore the relationship between 24-month progression-free survival (PFS24) and subsequent overall survival (sOS) as well as loss of lifetime (LoL) in NPC patients. sOS is defined as survival from the 24-month point or progression within 24 months leading to mortality. LoL represents the reduction in life expectancy due to NPC, compared to the general population matched by age, sex, and calendar year. The standardized mortality ratio (SMR) is defined as the ratio of observed mortality to expected mortality. The study included 6315 patients from nonendemic and endemic regions of China. Among them, 5301 patients (83.9%) achieved PFS24, with a 5-year sOS of 90.2% and an SMR of 1.0. Over a 10-year period following treatment, the mean LoL was only 0.01 months/year. For most subgroups, patients achieving PFS24 exhibited comparable sOS and LoL with the general population. However, patients failing to achieve PFS24 showed significantly worse outcomes, with 5-year sOS of 21.9%, SMR of 23.7, and LoL of 6.48 months/year. These notable outcome disparities highlight the importance of PFS24 in NPC risk stratification, patient monitoring, and study design.
Authors
- Xuesong Chen (ORCID: https://orcid.org/0009-0001-6273-9850)
- Junlin Yi (ORCID: https://orcid.org/0000-0002-7083-0216)
- Yang Liu (ORCID: https://orcid.org/0000-0001-8320-2756)
- Jingwei Luo (ORCID: https://orcid.org/0000-0003-3620-3945)
- Ye‐Xiong Li (ORCID: https://orcid.org/0000-0003-0985-235X)
- Runye Wu (ORCID: https://orcid.org/0009-0002-6959-5842)
- Kai Wang (ORCID: https://orcid.org/0000-0003-2155-1445)
- Ye Zhang (ORCID: https://orcid.org/0000-0001-9215-9024)
- Jingbo Wang (ORCID: https://orcid.org/0000-0001-7086-8401)
- Yuan Qu (ORCID: https://orcid.org/0000-0001-7297-0282)
- Yaqian Han (ORCID: https://orcid.org/0009-0005-7733-3799)
- Xiaodong Huang (ORCID: https://orcid.org/0000-0002-5815-7655)
- Mei Feng
- Qiuyan Chen (ORCID: https://orcid.org/0000-0001-9637-4995)
- Jianghu Zhang
Institutions
- Central South University (CN)
- University of Electronic Science and Technology of China (CN)
- Sun Yat-sen University (CN)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Third People's Hospital of Chengdu (CN)
- Hunan Cancer Hospital (CN)
- Sichuan Cancer Hospital (CN)
- Cancer Hospital of Chinese Academy of Medical Sciences (CN)
- Sun Yat-sen University Cancer Center (CN)
- State Key Laboratory of Oncology in South China
Publication Details
- Journal
- MedComm
- Published
- 2025-03-20
- DOI
- https://doi.org/10.1002/mco2.70143
- Citations
- 2
- Primary Topic
- Head and Neck Cancer Studies
- Type
- article
- Field-Weighted Citation Impact
- 3.70
Funders
- Beijing Xisike Clinical Oncology Research Foundation
- National Natural Science Foundation of China
- Chinese Academy of Medical Sciences
- National Key Research and Development Program of China